D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions

Journal of Psychiatric Research

Volumn 47, Issue 10, 2013, Pages 1455-1461

  Smits, Jasper A J ^a   Rosenfield, David ^a   Otto, Michael W ^b   Marques, Luana ^c   Davis, Michelle L ^a   Meuret, Alicia E ^b   Simon, Naomi M ^c   Pollack, Mark H ^d   Hofmann, Stefan G ^b  

^a SOUTHERN METHODIST UNIVERSITY   (United States)

^b BOSTON UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CBT; Cognitive behavioral therapy; D cycloserine; Exposure therapy; Fear extinction; Moderators; Social anxiety disorder; Social phobia

Indexed keywords

CYCLOSERINE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXPOSURE THERAPY; FEAR; FEAR EXTINCTION; FEMALE; FOLLOW UP; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL PHOBIA; TREATMENT OUTCOME;

CBT; COGNITIVE BEHAVIORAL THERAPY; D-CYCLOSERINE; EXPOSURE THERAPY; FEAR EXTINCTION; MODERATORS; SOCIAL ANXIETY DISORDER; SOCIAL PHOBIA;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CYCLOSERINE; DOUBLE-BLIND METHOD; FEAR; FEMALE; HUMANS; IMPLOSIVE THERAPY; MALE; MODELS, STATISTICAL; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84881557781     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.06.020     Document Type: Article

References (41)

1. Aiken L.S., West S.G. Multiple regression: testing and interpreting interactions 1991, Sage Publications, Newbury Park, CA.
2. Berry A.C., Rosenfield D., Smits J.A. Extinction retention predicts improvement in social anxiety symptoms following exposure therapy. Depression and Anxiety 2009, 26:22-27.
3. Bouton M.E., Vurbic D., Woods A.M. d-cycloserine facilitates context-specific fear extinction learning. Neurobiology of Learning and Memory 2008, 90:504-510.
4. Cook T.D., Steiner P.M. Case matching and the reduction of selection bias in quasi-experiments: the relative importance of pretest measures of outcome, of unreliable measurement, and of mode of data analysis. Psychological Methods 2010, 15:56-68.
5. Craske M.G., Kircanski K., Zelikowsky M., Mystkowski J., Chowdhury N., Baker A. Optimizing inhibitory learning during exposure therapy. Behaviour Research and Therapy 2008, 46:5-27.
6. Davis M., Ressler K., Rothbaum B.O., Richardson R. Effects of d-cycloserine on extinction: translation from preclinical to clinical work. Biological Psychiatry 2006, 60:369-375.
7. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis-i disorders, clinician version 2001, American Psychiatric Publishing, Inc., Arlington, VA.
8. Goldin P.R., Ziv M., Jazaieri H., Werner K., Kraemer H., Heimberg R.G., et al. Cognitive reappraisal self-efficacy mediates the effects of individual cognitive-behavioral therapy for social anxiety disorder. Journal of Consulting and Clinical Psychology 2012, 80(6):1034-1040.
9. Greenberg P.E., Sisitsky T., Kessler R.C., Finkelstein S.N., Berndt E.R., Davidson J.R., et al. The economic burden of anxiety disorders in the 1990s. Jounal of Clinical Psychiatry 1999, 60:427-435.
10. Guastella A.J., Dadds M.R., Lovibond P.F., Mitchell P., Richardson R.A. Arandomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. Journal of Psychiatric Research 2007, 41:466-471.
11. Guastella A.J., Richardson R., Lovibond P.F., Rapee R.M., Gaston J.E., Mitchell P., et al. Arandomized controlled trial of the effect of d-cycloserine on enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry 2008, 63:544-549.
12. Guy W. Clinical global impression. Manual for the ECDEU assessment battery 1970.
13. Hamer R.M., Simpson P.M. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. American Journal of Psychiatry 2009, 166:639-641.
14. Hayes S.A., Hope D.A., Heimberg R.G. The pattern of subjective anxiety during in-session exposures over the course of cognitive-behavior therapy for clients with social anxiety disorder. Behaviour Therapy 2008 Sep, 39(3):286-299.
15. Heimberg R.G., Becker R.E. Cognitive-behavioral group therapy for social phobia: basic mechanisms and clinical strategies 2002, Guilford Press, New York, NY.
16. Hofmann S.G. Cognitive mediation of treatment change in social phobia. Journal of Consulting and Clinical Psychology 2004 Jun, 72(3):393-399.
17. Hofmann S.G. Cognitive factors that maintain social anxiety disorder: a comprehensive model and its treatment implications. Cognitive Behavior Therapy 2007, 36(4):193-209.
18. Hofmann S.G., Meuret A.E., Smits J.A., Simon N.M., Pollack M.H., Eisenmenger K., et al. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Archives of General Psychiatry 2006, 63:298-304.
19. Hofmann S.G., Smits J.A. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. Journal of Clinical Psychiatry 2008 Apr, 69(4):621-632.
20. Hofmann S.G., Otto M.W. Cognitive behavioral therapy for social anxiety disorder: evidence-based and disorder-specific treatment techniques 2008, Routledge, London.
21. Hofmann S.G., Smits J.A., Asnaani A., Gutner C.A., Otto M.W. Cognitive enhancers for anxiety disorders. Pharmacology Biochemestry and Behavior 2011, 99:275-284.
22. Hofmann S.G., Smits J.A., Rosenfield D., Simon N.M., Otto M.W., Meuret A.E., et al. d-cycloserine as augmentation strategy of cognitive behavioral therapy for social anxiety disorder. American Journal of Psychiatry 2013, 170:751-758.
23. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey replication. Archives of General Psychiatry 2005, 62(6):617-627.
24. Kushner M.G., Kim S.W., Donahue C., Thuras P., Adson D., Kotlyar M., et al. d-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry 2007, 62:835-838.
25. Lee J.L., Milton A.L., Everitt B.J. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. Journal of Neuroscience 2006, 26:10051-10056.
26. Liebowitz M.R. Social phobia. Modern Problems in Pharmacopsychiatry 1987, 22:141-173.
27. Liebowitz M.R., Schneier F., Campeas R., Hollander E., Hatterer J., Fyer A., et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Archives of General Psychiatry 1992, 49:290-300.
28. Litz B.T., Salters-Pedneault K., Steenkamp M.M., Hermos J.A., Bryant R.A., Otto M.W., et al. Arandomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder. Journal of Psychiatric Research 2012, 46:1184-1190.
29. Meuret A.E., Seidel A., Rosenfield B., Hofmann S.G., Rosenfield D. Does fear reactivity during exposure predict panic symptom reduction?. Journal of Consulting and Clinical Psychology 2012, 80:773-785.
30. Otto M.W., Tolin D.F., Simon N.M., Pearlson G.D., Basden S., Meunier S.A., et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biological Psychiatry 2010, 67:365-370.
31. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., et al. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry 2004, 61:1136-1144.
32. Smits J.A., Hofmann S.G., Rosenfield D., DeBoer L.D., Costa P.T., Simon N.M., et al. d-Cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. Journal of Consulting and Clininical Psychology 2013, (in press).
33. Smits J.A., Powers M.B., Buxkamper R., Telch M.J. The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation. Behaviour Research and Therapy 2006, 44(12):1773-1785.
34. Smits J.A., Julian K., Rosenfield D., Powers M.B. Threat reappraisal as a mediator of symptom change in cognitive-behavioral treatment of anxiety disorders: a systematic review. Journal of Consulting and Clininical Psychology 2012, 80(4):624-635.
35. Smits J.A., Rosenfield D., McDonald R., Telch M.J. Cognitive mechanisms of social anxiety reduction: an examination of specificity and temporality. Journal of Consulting and Clinical Psychology 2006, 74(6):1203-1212.
36. Smits J.A., Rosenfield D., Otto M.W., Powers M.B., Hofmann S.G., Telch M.J., et al. d-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biological Psychiatry 2013, 73:1054-1058.
37. Storch E.A., Merlo L.J., Bengtson M., Murphy T.K., Lewis M.H., Jacob Yang MC., et al. d-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology 2007, 22:230-237.
38. Tart C.D., Handelsman P.R., DeBoer L.B., Rosenfield D., Pollack M.H., Hofmann S.G., et al. Augmentation of exposure therapy with post-session administration of d-cycloserine. Journal of Psychiatric Research 2013, 47:168-174.
39. Weber M., Hart J., Richardson R. Effects of d-cycloserine on extinction of learned fear to an olfactory cue. Neurobiology of Learning and Memory 2007, 87:476-482.
40. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., et al. Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry 2008, 165:335-341.
41. Wolpe J. Psychotherapy by reciprocal inhibition 1958, Stanford University Press, Palo Alto, CA.